As I See It: Anti-corporation protests

Share this article:
James G. Dickinson
James G. Dickinson

As the country heads into another winter of discontent and presidential election season, anti-corporation protests on Wall Street and beyond send a message that pharmaceutical marketers and regulators alike should ponder.

It is this: young voters want an end to the industry-government status quo. That could upset relationships which have evolved under cover for two decades.

“I want my government back!” read many placards in the New York crowd after 700 people were arrested for disorderliness. Another proclaimed: “I could lose my job for having a voice,” voicing frustration over diminished First Amendment rights.

This message challenges a complacent FDA/regulated industry coalition that strives to do business increasingly behind closed doors while citing improved transparency—to each other, but maybe not to those “disenfranchised” protesters. New HHS guidelines in September brought tighter controls on media access to internal happenings.

On the streets, the ruckus felt like the “Arab spring” as TV broadcasts promised the movement's fusion with labor-union discontent. And if FDA and its regulated industries feel immune to anger over such scourges as loss of health insurance and rising drug shortages, they may be in for a rude awakening.

Street demonstrations have shaken up FDA before. In October 1988, AIDS protesters shut down the agency's Rockville headquarters for several hours. Approval of AIDS drugs was duly expedited.

Since then, FDA and other federal agencies have insulated themselves from direct access due to “security” concerns—a process that might well have lost them some sensitivity to public concerns.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in As I See It

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in As I See It

As I See It: Patient Centricity

As I See It: Patient Centricity

A patient who is diagnosed earlier and receives the most efficacious treatment is the least expensive

As I See It: FDA's social-media moves

As I See It: FDA's social-media moves

FDA has insisted that its antique regulations can address every new promotional challenge

As I See It: FDA and marketing materials

As I See It: FDA and marketing materials

The more clarity that FDA provides, the more confident companies can be in their medical communications